Press Releases

Month Year

Get News Alerts by Email

Jul 5, 2022

The U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...
Jun 21, 2022

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal

Second Publication on the Potential Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its...
Jun 2, 2022

Eisai to Present Latest Data on LEMBOREXANT at the 36th Annual Sleep 2022 Meeting

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today a total of seven poster presentations including the latest data on its in-house discovered orexin receptor...
May 9, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application Of Lecanemab For Early Alzheimer's Disease Under the Accelerated Approval Pathway

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...
Apr 26, 2022

Long-term Health Outcomes Using Simulation Model of Investigational Lecanemab in Patients with Early Alzheimer's Disease Published in a Peer-Reviewed Journal, Neurology and Therapy

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational anti-amyloid-beta (Aβ) protofibril antibody...
Apr 7, 2022

Eisai Statement on The Centers For Medicare And Medicaid Services’ National Coverage Determination with Coverage with Evidence Development for Monoclonal Antibodies Directed Against Amyloid for the Treatment Of Alzheimer’s Disease

Eisai stands with people living with Alzheimer’s disease (AD), health care professionals and other members of our AD community. We respect that the Centers for Medicare and Medicaid Services...
Apr 4, 2022

Geisinger, Eisai team up to study use of artificial intelligence for early detection and identification of cognitive impairment that could indicate dementias, including Alzheimer's disease

Research collaboration will test novel algorithm's effectiveness on Geisinger data DANVILLE, Pa. and NUTLEY, N.J., April 4, 2022 /PRNewswire/ -- Geisinger and Eisai Inc. today announced a...
Mar 31, 2022

Eisai to Present Data on Neurology Portfolio in the Areas of Alzheimer's Disease, Sleep and Epilepsy at the 74th American Academy of Neurology® (AAN) Annual Meeting

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the company will present research from its robust neurology portfolio, including the findings on lecanemab, an...
Mar 22, 2022

Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimer's Disease

The Content Presented at the International Conference on Alzheimer's & Parkinson's Diseases: (AD/PD™ 2022) KOBE, Japan and TOKYO, March 22, 2022 /PRNewswire/ -- Sysmex Corporation (Chairman and CEO:
Mar 21, 2022

Latest Findings on Lecanemab - Clinical Efficacy, ARIA Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented At AD/PD™ 2022 Annual Meeting

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...

Show per page

Open a printable version of this page
Email the URL of this page to a friend